Biotech entity
pharma is the sole category represented across all 4 tracked stories. They are better corroborated than the beat average, carrying 9 original sources each against 3.6 for the same window. AdvaMed is the most frequent co-covered peer, appearing in 1 of the 4 tracked stories.
Last mentioned: Jul 25, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 4 tracked stories. They are better corroborated than the beat average, carrying 9 original sources each against 3.6 for the same window. AdvaMed is the most frequent co-covered peer, appearing in 1 of the 4 tracked stories. The 24-day window averages about 1.2 stories each week. At 6.8, the average consequence score sits above the same-window beat average of 6. This profile follows 4 Biotech stories mentioning Medtronic across the period from February 18, 2026 to March 13, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 292 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Medtronic. Shared-story counts are live from our verified record — not editorial picks.
The Environmental Protection Agency (EPA) has moved to ease pollution restrictions on ethylene oxide (EtO), a critical chemical used to sterilize half of all U.S. medical devices. This regulatory shift aims to prevent potential healthcare supply chain disruptions but faces immediate backlash from environmental and public health advocates.
The global minimally invasive surgical devices market is projected to grow at a 7% CAGR through 2034, driven by technological advancements and a shift toward outpatient care. This growth reflects a broader healthcare transition prioritizing reduced recovery times and improved patient outcomes.
The Australian government is significantly reducing subsidies for high-cost spinal cord stimulators following reports of severe patient injuries and a lack of clinical efficacy. This regulatory shift targets a multi-million dollar sector of the medical device market, forcing manufacturers to justify the high price tags of chronic pain technologies.
US equities faced a volatile session as investors reassessed the 'dark side' of AI disruption, dragging the Nasdaq into its fifth consecutive week of losses. Within the healthcare sector, attention is fixed on Medtronic's earnings and Masimo's performance as the industry grapples with shifting valuations.
Source: Benzinga · Yahoo Finance
Medtronic is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
